Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Squamous cell carcinoma (SCC) is a malignant skin cancer arising from abnormal growth of squamous epithelial cells. According to Chengling Liu et al., 2025, global cutaneous squamous cell carcinoma burden is significant, with the United States reporting nearly 1.8 million cases and China about 260 thousand cases, while U.S. ASPR is roughly 300 per 100,000 population. As per squamous cell carcinoma pipeline analysis by Expert Market Research, emerging immunotherapy, targeted therapy, and novel biologics are strengthening the drug development landscape. The growing focus on precision medicine, early diagnosis, and advanced oncology pipelines is expected to drive market expansion in the coming years.
-
Major companies involved in the squamous cell carcinoma pipeline analysis include CSPC Megalith Biopharmaceutical Co., Ltd., Shanghai Junshi Bioscience Co., Ltd., Boehringer Ingelheim, and others.
-
Leading drugs currently in the pipeline include SYS6010+SG001, JS212, BI 770371 + Pembrolizumab, and others.
-
Expanding immunotherapy, rising biomarker-driven precision medicine, and accelerated targeted therapy clinical trials, including EGFR and PD-1/PD-L1 inhibitors, are driving robust pipeline development and innovation in treatment options.
Report Coverage
The Squamous Cell Carcinoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into squamous cell carcinoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for squamous cell carcinoma. The squamous cell carcinoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The squamous cell carcinoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with squamous cell carcinoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to squamous cell carcinoma.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Squamous Cell Carcinoma Pipeline Outlook
Squamous cell carcinoma is a malignant skin cancer that originates in the squamous cells of the epidermis. It primarily develops following cumulative ultraviolet radiation exposure, which induces DNA damage and abnormal cellular proliferation. The disease most frequently affects sun-exposed areas, including the face, scalp, ears, neck, and hands, and may invade surrounding tissues if left untreated.
Squamous cell carcinoma treatment depends on tumor stage, size, and location, and commonly includes surgical excision, radiation therapy, immunotherapy, and topical or systemic therapies for advanced or recurrent disease. Early diagnosis and timely intervention significantly improve clinical outcomes and reduce recurrence risk. Libtayo (cemiplimab), a programmed cell death protein 1 (PD-1) inhibitor, represents a significant advancement in the squamous cell carcinoma drug pipeline. In October 2025, the U.S. Food and Drug Administration approved the therapy for high-risk cutaneous squamous cell carcinoma following surgery and radiation. Reported in January 2026, the approval was supported by improved disease-free survival, establishing a new immunotherapy standard for eligible patients.
Squamous Cell Carcinoma Epidemiology
The pipeline continues to gain momentum as the rising incidence of squamous cell carcinoma increases the demand for innovative drug development and targeted therapies. According to Chengling Liu et al. (2025), the United States reported 1,820,873 cutaneous squamous cell carcinoma cases in 2021, with the highest age-standardized prevalence rate of 300.40 per 100,000 individuals. According to Ryoko Rikitake et al. (2026), Japan records approximately 30,000 head and neck cancer cases annually, while P. K. Asmin et al. (2024) reported that squamous cell carcinoma accounts for 90-95% of oral cancer cases in India, supporting continued pipeline analysis and therapeutic innovation.
Squamous Cell Carcinoma – Pipeline Therapeutic Assessment
This section of the report covers the analysis of squamous cell carcinoma drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase 1)
- Preclinical and Discovery Stage Products
By Drug Class
The squamous cell carcinoma pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Peptides
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Squamous Cell Carcinoma Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total squamous cell carcinoma clinical trials, accounting for 58%, reflecting strong clinical advancement and significant market growth potential. It is followed by phase I at 25% with a robust early-stage innovation pipeline, and phase III with 14%, supporting late-stage development, commercialization prospects, and the continued expansion of the market.
Squamous Cell Carcinoma Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the squamous cell carcinoma pipeline analysis include small molecules, monoclonal antibodies, and peptides. The squamous cell carcinoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for squamous cell carcinoma. Emerging investigational therapies for squamous cell carcinoma include immune checkpoint inhibitors, EGFR-targeted agents, and novel monoclonal antibodies designed to enhance anti-tumor activity. For instance, PD-1/PD-L1 inhibitors are being evaluated to restore immune recognition of cancer cells. Additionally, targeted agents are under clinical assessment to improve tumor suppression, survival outcomes, and treatment response in advanced disease.
Squamous Cell Carcinoma Clinical Trials – Key Players
The EMR report for the squamous cell carcinoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed squamous cell carcinoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in squamous cell carcinoma clinical trials:
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Shanghai Junshi Bioscience Co., Ltd.
- Boehringer Ingelheim
- Sichuan Baili Pharmaceutical Co., Ltd.
- Incyte Corporation
- EvolveImmune United, Inc.
- Merck Sharp & Dohme LLC
- Genentech, Inc.
- Beijing Immupeutics Medicine Technology Limited
- Naveris, Inc.
Squamous Cell Carcinoma – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for squamous cell carcinoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of squamous cell carcinoma drug candidates.
Drug: SYS6010+SG001
SYS6010 (EGFR antibody-drug conjugate) is being developed and is sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. The phase II/III multicenter study is evaluating intravenous SYS6010, administered every 2 weeks at 3.6 mg/kg, in first-line advanced or metastatic esophageal squamous cell carcinoma. The drug comprises an EGFR-specific antibody, a cleavable linker, and a topoisomerase I inhibitor (JS-1), designed to deliver targeted cytotoxic activity. The study is examining efficacy and safety, determining MTD and RP2D, and comparing outcomes versus investigator’s choice standard of care with or without chemotherapy. The study is expected to start in December 2025 and complete by December 2030.
Drug: JS212
JS212 is a recombinant humanized EGFR/HER3 bispecific antibody-drug conjugate (ADC) being administered intravenously every three weeks. Sponsored by Shanghai Junshi Bioscience Co., Ltd., a Phase 2 open-label, multicenter study is evaluating JS212 combination therapy with JS001 and 5-FU in patients with advanced esophageal squamous cell carcinoma. The study is examining the safety, tolerability, and preliminary efficacy of the regimen while assessing antitumor activity in approximately 280 patients. The trial is scheduled for primary completion by June 2027 and study completion by April 2028.
Drug: BI 770371 + Pembrolizumab
BI 770371 is a novel anti-SIRPα monoclonal antibody being developed and sponsored by Boehringer Ingelheim. A Phase Ib open-label randomized clinical trial is evaluating BI 770371 in combination with pembrolizumab, with or without cetuximab, versus pembrolizumab monotherapy in first-line metastatic or recurrent head and neck squamous cell carcinoma. The study is examining whether these intravenous infusion-based combinations are helping tumors shrink by enhancing immune response through CD47–SIRPα blockade, restoring macrophage-mediated tumor killing, while pembrolizumab inhibits PD-1 and cetuximab targets EGFR signaling. The study is active, not recruiting, and is expected to be completed in August 2027.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Squamous Cell Carcinoma Pipeline Insight Report
- Which companies/institutions are leading the squamous cell carcinoma drug development?
- Which company is leading the squamous cell carcinoma pipeline development activities?
- What is the current squamous cell carcinoma commercial assessment?
- What are the opportunities and challenges present in the squamous cell carcinoma pipeline landscape?
- What is the efficacy and safety profile of squamous cell carcinoma pipeline drugs?
- Which company is conducting major trials for squamous cell carcinoma drugs?
- Which companies/institutions are involved in squamous cell carcinoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in squamous cell carcinoma?
Reasons To Buy This Report
The squamous cell carcinoma pipeline analysis report provides a strategic overview of the latest and future landscape of treatments for squamous cell carcinoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into squamous cell carcinoma collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market
Recurrent Head and Neck Cancer Squamous Cell Carcinoma Drug Pipeline Analysis Report
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
